Patents or Trade Secrets? When to Patent in Deep Tech Innovation

​
May 11, 2026

Why IP Strategy Matters for Deep Tech Companies

Protecting your business and products from being copied or otherwise exploited is always important, particularly for companies developing deep tech technologies. Advanced hardware, electronics, and the processes used to design, manufacture, or operate them, require a particular approach. Long development cycles and high upfront investment often delay commercial returns, making it essential to adopt an IP strategy that reflects how value is created, where technical advantage truly lies, and how competitors could realistically gain access to it.

Properly protected IP is widely recognised as a way of enhancing company value. This can be achieved by preventing others from using your technology without permission, but equally by creating defensible barriers that deter entry or imitation. A recurring strategic question for deep tech companies is whether protection should take the form of patents, trade secrets, or, more often, a carefully structured combination of the two.

Reverse Engineering and the Risk of Imitation

For a competitor to copy a technology, the relevant technical details must be known or discoverable. Physical hardware, such as circuit designs, can sometimes be reverse-engineered, although complex systems may require sophisticated techniques, including X‑ray imaging, electron microscopy, or focused ion beam analysis. While these approaches can be costly and time‑consuming, they may still be commercially viable where the upside is large enough.

Importantly, competitive advantage in deep tech does not arise solely from products. Many businesses also rely heavily on processes: manufacturing methods, calibration routines, materials processing steps, test methodologies, control algorithms, or system‑level integration techniques. These processes often deliver critical improvements in performance, yield, reliability, or cost, yet may not be directly observable from the final product.

Detectability and Enforceability in Practice

In some business models, disclosure is unavoidable. Semiconductor IP, for example, may be licensed in the form of RTL code such as Verilog or VHDL, making the underlying design visible to customers and their engineers. In these scenarios, trade secrets alone can be fragile. Patent protection may provide clearer and more enforceable rights, particularly where multiple organisations need access to the same core technology.

Detectability plays a central role in the patent versus trade secret decision. If a competitor cannot readily determine how a technology works, it may also be difficult for the rights holder to detect or prove infringement. Patents are often best suited to technologies that are likely to be discovered through product inspection, disclosed to third parties, or independently developed. They provide a defined scope of protection and a structured enforcement framework. When drafted with detectability in mind, patents can be aligned with externally observable behaviour or measurable system outputs, improving their practical enforceability even for complex technologies.

Using Trade Secrets to Protect Internal Know‑How

Trade secrets, by contrast, are often well suited to internally used processes and know‑how that never need to be disclosed outside the organisation. This includes manufacturing techniques, tuning parameters, workflow optimisations, and other operational knowledge. Effective trade secret protection depends on technical, contractual, and organisational controls, including restricted access, confidentiality obligations, and careful documentation. In the EU, this requires compliance with the Trade Secrets Directive (EU Directive 2016/94).

Employee mobility presents additional challenges. Process‑based know‑how is often harder to protect once key personnel move to competitors, particularly where similar results can be achieved through parallel development. In such cases, patents covering core technical concepts, even where specific implementation details remain confidential, can provide a valuable backstop.

Combining Patents and Trade Secrets for Stronger Protection

In practice, the strongest deep tech IP strategies deliberately combine patents and trade secrets. Patents can secure protection for externally visible innovations and strategically important technical ideas, while trade secrets safeguard sensitive processes and execution know‑how that deliver practical advantage. Determining the right balance is highly technology‑specific and closely tied to commercial objectives.

‍

Early advice from experienced patent attorneys is therefore critical. At EIP, we work with companies developing complex deep tech systems to build IP strategies that align legal protection with technical reality and business goals. Through our Ampliphy offering, clients gain access to patent attorneys specialising in electronics, semiconductors, and advanced processes, ensuring informed decisions at the intersection of innovation, IP, and commercial strategy. To explore how a combined patent and trade secret strategy could work for your technology, contact Andrew Thompson or Filip Jörgensen for a discussion.

‍

‍

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​